Patrick Darken

2.9k citations

73 papers · 1.8k indexed · 1 hit paper · h-index 18

Impact in

Pulmonary and Respiratory Medicine top 1%
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Respiratory and Cough-Related Research
- Pulmonary Hypertension Research and Treatments
Physiology top 2%
- Asthma and respiratory diseases

Papers in ⓘ

Pulmonary and Respiratory Medicine 61
- Chronic Obstructive Pulmonary Disease (COPD) Research 52
- Inhalation and Respiratory Drug Delivery 37
- Respiratory and Cough-Related Research 17
- Respiratory Support and Mechanisms 12
Physiology 43
- Asthma and respiratory diseases 43

Co-authors: Colin Reisner (38 shared papers)Gary T. Ferguson (23 shared papers)Paul Dorinsky (33 shared papers)Klaus F. Rabe (24 shared papers)Shaila Ballal (17 shared papers)Magnus Aurivillius (18 shared papers)Chen Wang (7 shared papers)Fernando J. Martínez (24 shared papers)
Journals: CHEST Journal (7 papers)International Journal of COPD (6 papers)Respiratory Medicine (6 papers)Respiratory Research (4 papers)Journal of Allergy and Clinical Immunology (3 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Patrick Darken

70 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD 2020 · 374 citations

Peers

Countries citing papers authored by Patrick Darken

Since Specialization

Citations

This map shows the geographic impact of Patrick Darken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Darken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Darken more than expected).

Fields of papers citing papers by Patrick Darken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Darken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Darken. The network helps show where Patrick Darken may publish in the future.

Co-authors

The 25 scholars most cited alongside Patrick Darken, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick Darken Line = papers co-authored together Patrick Darken links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 73 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD New England Journal of Medicine ·Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, Roopa Trivedi, Earl St. Rose, Shaila Ballal, Julie McLaren, Patrick Darken, Magnus Aurivillius, Colin Reisner, Paul Dorinsky Hit paper breakdown →	2020	374
2	The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD CHEST Journal ·Nicola A. Hanania, Patrick Darken, Donald H. Horstman, Colin Reisner, Benjamin Lee, Suzanne E. Davis, Tushar Shah	2003	265
3	Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial The Lancet Respiratory Medicine ·Gary T. Ferguson, Klaus F. Rabe, Fernando J. Martínez, Leonardo M. Fabbri, Chen Wang, Masakazu Ichinose, Eric Bourne, Shaila Ballal, Patrick Darken, Kiernan DeAngelis, Magnus Aurivillius, Paul Dorinsky, Colin Reisner	2018	252
4	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study American Journal of Respiratory and Critical Care Medicine ·Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson, Jadwiga A. Wedzicha, Dave Singh, Chen Wang, Kimberly Rossman, Earl St. Rose, Roopa Trivedi, Shaila Ballal, Patrick Darken, Magnus Aurivillius, Colin Reisner, Paul Dorinsky	2020	147
5	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD CHEST Journal ·Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson, Leonardo M. Fabbri, Stephen I. Rennard, Gregory Feldman, Sanjay Sethi, Selwyn Spangenthal, Gregory Gottschlich, Roberto Rodríguez-Roisin, Samir Arora, Thomas M. Siler, Shahid Siddiqui, Patrick Darken, Tracy Fischer, Andrea Maes, Michael A. Golden, Chad Orevillo, Colin Reisner	2016	94
6	Cardiovascular Safety of Salmeterol in COPDa CHEST Journal ·Gary T. Ferguson, Christian Funck‐Brentano, Tracy Fischer, Patrick Darken, Colin Reisner	2003	74
7	Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis Journal of Allergy and Clinical Immunology ·Paul H. Ratner, Mark A. Wingertzahn, (unknown), Frank C. Hampel, Patrick Darken, Tanush Shah	2006	52
8	Association between COPD exacerbations and lung function decline during maintenance therapy Thorax ·Marjan Kerkhof, Jaco Voorham, Paul Dorinsky, Claudia Cabrera, Patrick Darken, Janwillem Kocks, Mohsen Sadatsafavi, Don D. Sin, Victoria Carter, David Price	2020	38
9	Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD CHEST Journal ·Fernando J. Martínez, Leonardo M. Fabbri, Gary T. Ferguson, Chad Orevillo, Patrick Darken, Ubaldo J. Martin, Colin Reisner	2017	37
10	Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis Annals of Allergy Asthma & Immunology ·Paul H. Ratner, Mark A. Wingertzahn, Julius H. van Bavel, Frank C. Hampel, Patrick Darken, S. Hellbardt, Sheldon Brookman, Tushar Shah	2006	25
11	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol Respiratory Medicine ·Klaus F. Rabe, Fernando J. Martínez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, Roopa Trivedi, Earl St. Rose, Shaila Ballal, Julie McLaren, Patrick Darken, Colin Reisner, Paul Dorinsky	2019	24
12	A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease Respiratory Research ·Colin Reisner, Leonardo M. Fabbri, Edward Kerwin, Charles Fogarty, Selwyn Spangenthal, Klaus F. Rabe, Gary T. Ferguson, Fernando J. Martínez, James F. Donohue, Patrick Darken, Earl St. Rose, Chad Orevillo, Shannon Strom, Tracy Fischer, Michael A. Golden, Sarvajna Dwivedi	2017	21
13	<p>The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline</p> International Journal of COPD ·Marjan Kerkhof, Jaco Voorham, Paul Dorinsky, Claudia Cabrera, Patrick Darken, Janwillem Kocks, Mohsen Sadatsafavi, Don D. Sin, Victoria Carter, David Price	2020	21
14	The attributable estimand: A new approach to account for intercurrent events Pharmaceutical Statistics ·Patrick Darken, Jack Nyberg, Shaila Ballal, David Wright	2020	21
15	A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD Respiratory Medicine ·Donald P. Tashkin, Fernando J. Martínez, Roberto Rodríguez-Roisin, Charles Fogarty, Mark H. Gotfried, Michael Denenberg, Gregory Gottschlich, James F. Donohue, Chad Orevillo, Patrick Darken, Earl St. Rose, Shannon Strom, Tracy Fischer, Michael A. Golden, Colin Reisner	2016	20
16	Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease BMC Pulmonary Medicine ·Stephen I. Rennard, Charles Fogarty, Colin Reisner, Carlos Fernández, Tracy Fischer, Michael A. Golden, Earl St. Rose, Patrick Darken, Gregory Tardie, Chadwick J. Orevillo	2014	20
17	VIRGINIA USA WATER QUALITY, 1978 TO 1995: REGIONAL INTERPRETATION¹ JAWRA Journal of the American Water Resources Association ·Carl E. Zipper, Golde I. Holtzman, Patrick Darken, Jason J. Gildea, Roger E. Stewart	2002	18
18	Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis Advances in Therapy ·Gary T. Ferguson, Patrick Darken, Shaila Ballal, Mohd Kashif Siddiqui, Barinder Singh, Sumeet Attri, Ulf Holmgren, Enrico De Nigris	2020	17
19	Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial Therapeutic Advances in Respiratory Disease ·Klaus F. Rabe, Fernando J. Martínez, Dave Singh, Roopa Trivedi, Martin Jenkins, Patrick Darken, Magnus Aurivillius, Paul Dorinsky	2021	17
20	Detecting changes in trends in water quality using modified Kendall's tau Environmetrics ·Patrick Darken, Golde I. Holtzman, Eric P. Smith, Carl E. Zipper	2000	15

About Patrick Darken

Patrick Darken is a scholar working on Pulmonary and Respiratory Medicine, Physiology, Immunology and Allergy, Sensory Systems and Statistics and Probability, having authored 73 papers that have together received 1.8k indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (52 papers), Asthma and respiratory diseases (43 papers), Inhalation and Respiratory Drug Delivery (37 papers), Respiratory and Cough-Related Research (17 papers), Respiratory Support and Mechanisms (12 papers), Allergic Rhinitis and Sensitization (6 papers), Statistical Methods in Clinical Trials (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.6k citations), Physiology (1.3k citations), Issues, ethics and legal aspects (24 citations), Immunology and Allergy (105 citations) and Emergency Medical Services (55 citations). Patrick Darken has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Colin Reisner, Gary T. Ferguson, Paul Dorinsky, Klaus F. Rabe, Shaila Ballal, Magnus Aurivillius, Chen Wang, Fernando J. Martínez, Earl St. Rose and Roopa Trivedi. Their work appears in journals such as CHEST Journal, International Journal of COPD, Respiratory Medicine, Respiratory Research and Journal of Allergy and Clinical Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact